Moderna : Le CMV, une base forte à la thèse d’investissement
>Une publication du T3 sans grande surprise - Avant-hier, la biotech américaine publiait ses résultats trimestriels qui ne révélaient que peu de surprise. La consommation de trésorerie est confirmée autour des 500 M$ pour l’année. Le management profite de cette publication pour donner une première guidance pour 2020 stipulant une consommation globalement identique c’est-à -dire comprise entre 490 M$ et 510 M$. La trésorerie estimée fin 2019 sera ainsi autour de 1....Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.